Massachusetts Attorney General Andrea Campbell and a few of her peers sued CVS on Wednesday, alleging the pharmacy giant for years failed to provide Medicaid members with access to the same discount as cash-paying customers. Campbell and attorneys general in Connecticut, Indiana and Oklahoma jointly filed a civil action after a whistleblower complaint in Washington, D.C., prompting the company to 'strongly dispute' the allegations.
A federal judge has sided with the FDA over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.
Americans spent $98 billion out of pocket on prescription drugs in 2024, marking a cumulative 25% increase over five years, according to an annual report from analytics firm IQVIA.
Amid ongoing anticipation over tariffs on pharmaceuticals, President Trump on Monday signed an executive order designed to lower regulatory hurdles and make it faster for drug companies to manufacture their products in the U.S. The move also includes plans to place more pressure on foreign drugmakers to comply with quality control inspections.
HHS Secretary Robert F. Kennedy Jr. will ask the CDC to develop new guidance for treating measles with drugs and vitamins. The move comes as Kennedy has faced criticism during this year's record measles outbreaks for remarks misleading people into thinking that measles infections are easily curable and inflating myths about measles vaccines.
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.